Targeted Cancer Therapy: Promise and Reality

Advances in Cancer Research

Volumn 97, Issue , 2007, Pages 295-319

  Klein, Shoshana ^a   Levitzki, Alexander ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BCR ABL PROTEIN; BEVACIZUMAB; CETUXIMAB; CISPLATIN; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMATINIB; INTERFERON; LAPATINIB; NUCLEAR FACTOR; ON 012380; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN INHIBITOR; PROTEIN KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MODEL; CANCER RADIOTHERAPY; CANCER RESISTANCE; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLON CARCINOMA; COLORECTAL CARCINOMA; DRUG TARGETING; EOSINOPHILIC LEUKEMIA; GASTROINTESTINAL STROMAL TUMOR; HEAD AND NECK CANCER; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TARGET CELL; TRANSGENIC ANIMAL; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; DRUG SCREENING ASSAYS, ANTITUMOR; FORECASTING; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MICE, TRANSGENIC; NEOPLASM PROTEINS; NEOPLASMS; NEOPLASTIC STEM CELLS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 34047150764     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-230X(06)97013-4     Document Type: Review

References (113)

1. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., and Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 100 (2003) 3983-3988
2. Almstrup K., Hoei-Hansen C.E., Wirkner U., Blake J., Schwager C., Ansorge W., Nielsen J.E., Skakkebaek N.E., Rajpert-De Meyts E., and Leffers H. Embryonic stem cell-like features of testicular carcinoma in situ revealed by genome-wide gene expression profiling. Cancer Res. 64 (2004) 4736-4743
3. Anafi M., Gazit A., Gilon C., Ben-Neriah Y., and Levitzki A. Selective interactions of transforming and normal abl proteins with ATP, tyrosine-copolymer substrates, and tyrphostins. J. Biol. Chem. 267 (1992) 4518-4523
4. Angstreich G.R., Matsui W., Huff C.A., Vala M.S., Barber J., Hawkins A.L., Griffin C.A., Smith B.D., and Jones R.J. Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors. Br. J. Haematol. 130 (2005) 373-381
5. Apperley J.F., Gardembas M., Melo J.V., Russell-Jones R., Bain B.J., Baxter E.J., Chase A., Chessells J.M., Colombat M., Dearden C.E., Dimitrijevic S., Mahon F.X., et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N. Engl. J. Med. 347 (2002) 481-487
6. Arnoletti J.P., Buchsbaum D.J., Huang Z.-q., Hawkins A.E., Khazaeli M.B., Kraus M.H., and Vickers S.M. Mechanisms of resistance to Erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells. J. Gastrointest. Surg. 8 (2004) 960-970
7. Awada A., Hendlisz A., Gil T., Bartholomeus S., Mano M., de Valeriola D., Strumberg D., Brendel E., Haase C.G., Schwartz B., and Piccart M. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br. J. Cancer 92 (2005) 1855-1861
8. Azam M., Latek R.R., and Daley G.Q. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112 (2003) 831-843
9. Banai S., Gertz S.D., Gavish L., Chorny M., Perez L.S., Lazarovichi G., Ianculuvich M., Hoffmann M., Orlowski M., Golomb G., and Levitzki A. Tyrphostin AGL-2043 eluting stent reduces neointima formation in porcine coronary arteries. Cardiovasc. Res. 64 (2004) 165-171
10. Becher O.J., and Holland E.C. Genetically engineered models have advantages over xenografts for preclinical studies. Cancer Res. 66 (2006) 3355-3358 ; discussion 3358-3359
11. Ben-Bassat H., Rosenbaum-Mitrani S., Hartzstark Z., Levitzki R., Chaouat M., Shlomai Z., Klein B.Y., Kleinberger-Doron N., Gazit A., Tsvieli R., and Levitzki A. Tyrphostins that suppress the growth of human papilloma virus 16-immortalized human keratinocytes. J. Pharmacol. Exp. Ther. 290 (1999) 1442-1457
12. Bibby M.C. Orthotopic models of cancer for preclinical drug evaluation: Advantages and disadvantages. Eur. J. Cancer 40 (2004) 852-857
13. Bonner J.A., Harari P.M., Giralt J., Azarnia N., Shin D.M., Cohen R.B., Jones C.U., Sur R., Raben D., Jassem J., Ove R., Kies M.S., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck 10.1056/NEJMoa053422. N. Engl. J. Med. 354 (2006) 567-578
14. Buchdunger E., Zimmermann J., Mett H., Meyer T., Muller M., Regenass U., and Lydon N.B. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc. Natl. Acad. Sci. USA 92 (1995) 2558-2562
15. Buchdunger E., Cioffi C.L., Law N., Stover D., Ohno-Jones S., Druker B.J., and Lydon N.B. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. 295 (2000) 139-145
16. Burdelya L., Catlett-Falcone R., Levitzki A., Cheng F., Mora L.B., Sotomayor E., Coppola D., Sun J., Sebti S., Dalton W.S., Jove R., and Yu H. Combination therapy with AG-490 and interleukin 12 achieves greater antitumor effects than either agent alone. Mol. Cancer Ther. 1 (2002) 893-899
17. Cao C., Shinohara E.T., Subhawong T.K., Geng L., Woon Kim K., Albert J.M., Hallahan D.E., Lu B., Coll-Mulet L., Iglesias-Serret D., Santidrian A.F., Cosialls A.M., et al. Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2 MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Mol. Cancer Ther. 5 (2006) 411-417
18. Cappuzzo F., Hirsch F.R., Rossi E., Bartolini S., Ceresoli G.L., Bemis L., Haney J., Witta S., Danenberg K., Domenichini I., Ludovini V., Magrini E., et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl. Cancer Inst. 97 (2005) 643-655
19. Cappuzzo F., Varella-Garcia M., Shigematsu H., Domenichini I., Bartolini S., Ceresoli G.L., Rossi E., Ludovini V., Gregorc V., Toschi L., Franklin W.A., Crino L., et al. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Clin. Oncol. 23 (2005) 5007-5018
20. Citri A., and Yarden Y. EGF-ERBB signalling: Towards the systems level. Nat. Rev. Mol. Cell Biol. 7 (2006) 505-516
21. Coll-Mulet L., Iglesias-Serret D., Santidrian A.F., Cosialls A.M., de Frias M., Castano E., Campas C., Barragan M., de Sevilla A.F., Domingo A., Vassilev L.T., Pons G., et al. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood 107 (2006) 4109-4114
22. Cortes J., O'Brien S., and Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 104 (2004) 2204-2205
23. De Keersmaecker K., and Cools J. Chronic myeloproliferative disorders: A tyrosine kinase tale. Leukemia 20 (2006) 200-205
24. Debiec-Rychter M., Dumez H., Judson I., Wasag B., Verweij J., Brown M., Dimitrijevic S., Sciot R., Stul M., Vranck H., Scurr M., Hagemeijer A., et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer 40 (2004) 689-695
25. Delvenne P., Hubert P., Jacobs N., Giannini S.L., Havard L., Renard I., Saboulard D., and Boniver J. The organotypic culture of HPV-transformed keratinocytes: An effective in vitro model for the development of new immunotherapeutic approaches for mucosal (pre)neoplastic lesions. Vaccine 19 (2001) 2557-2564
26. Donato N.J., Wu J.Y., Stapley J., Gallick G., Lin H., Arlinghaus R., and Talpaz M. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101 (2003) 690-698
27. Downward J. Targeting ras signalling pathways in cancer therapy. Nat. Rev. Cancer 3 (2003) 11-22
28. Elenbaas B., Spirio L., Koerner F., Fleming M.D., Zimonjic D.B., Donaher J.L., Popescu N.C., Hahn W.C., and Weinberg R.A. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev. 15 (2001) 50-65
29. Fiebig H.H., Maier A., and Burger A.M. Clonogenic assay with established human tumour xenografts: Correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur. J. Cancer 40 (2004) 802-820
30. Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., Vogel V., Robidoux A., Dimitrov N., Atkins J., Daly M., Wieand S., et al. Tamoxifen for prevention of breast cancer: Report of the national surgical adjuvant breast and bowel project P-1 study. J. Natl. Cancer Inst. 90 (1998) 1371-1388
31. Flores E.R., Allen-Hoffmann B.L., Lee D., Sattler C.A., and Lambert P.F. Establishment of the human papillomavirus type 16 (HPV-16) life cycle in an immortalized human foreskin keratinocyte cell line. Virology 262 (1999) 344-354
32. Georgantas III R.W., Tanadve V., Malehorn M., Heimfeld S., Chen C., Carr L., Martinez-Murillo F., Riggins G., Kowalski J., and Civin C.I. Microarray and serial analysis of gene expression analyses identify known and novel transcripts overexpressed in hematopoietic stem cells. Cancer Res. 64 (2004) 4434-4441
33. Geyer C., Cameron D., and Lindquist D. "42nd Annual Meeting of the American Society of Clinical Oncology." Atlanta, Georgia, USA (2006)
34. Golub T.R., Barker G.F., Lovett M., and Gilliland D.G. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77 (1994) 307-316
35. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., and Sawyers C.L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293 (2001) 876-880
36. Gumireddy K., Baker S.J., Cosenza S.C., John P., Kang A.D., Robell K.A., Reddy M.V., and Reddy E.P. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc. Natl. Acad. Sci. USA 102 (2005) 1992-1997
37. Hainsworth J.D., Sosman J.A., Spigel D.R., Edwards D.L., Baughman C., and Greco A. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J. Clin. Oncol. 23 (2005) 7889-7896
38. Heinrich M.C., Corless C.L., Demetri G.D., Blanke C.D., von Mehren M., Joensuu H., McGreevey L.S., Chen C.J., Van den Abbeele A.D., Druker B.J., Kiese B., Eisenberg B., et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 21 (2003) 4342-4349
39. Herzig M., and Christofori G. Recent advances in cancer research: Mouse models of tumorigenesis. Biochim. Biophys. Acta 1602 (2002) 97-113
40. Higashi T., Tsukada J., Kato C., Iwashige A., Mizobe T., Machida S., Morimoto H., Ogawa R., Toda Y., and Tanaka Y. Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: Report of two cases. Am. J. Hematol. 76 (2004) 275-278
41. Hirota S., Isozaki K., Moriyama Y., Hashimoto K., Nishida T., Ishiguro S., Kawano K., Hanada M., Kurata A., Takeda M., Muhammad Tunio G., Matsuzawa Y., et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279 (1998) 577-580
42. Hirota S., Ohashi A., Nishida T., Isozaki K., Kinoshita K., Shinomura Y., and Kitamura Y. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 125 (2003) 660-667
43. Hope K.J., Jin L., and Dick J.E. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat. Immunol. 5 (2004) 738-743
44. Huang S., Armstrong E.A., Benavente S., Chinnaiyan P., and Harari P.M. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): Combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res. 64 (2004) 5355-5362
45. Huang S.-M., and Harari P.M. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin. Cancer Res. 6 (2000) 2166-2174
46. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350 (2004) 2335-2342
47. Izumi Y., Xu L., di Tomaso E., Fukumura D., and Jain R.K. Tumour biology: Herceptin acts as an anti-angiogenic cocktail. Nature 416 (2002) 279-280
48. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., Feuer E.J., and Thun M.J. Cancer statistics, 2005. CA Cancer J. Clin. 55 (2005) 10-30
49. Ji H., Li D., Chen L., Shimamura T., Kobayashi S., McNamara K., Mahmood U., Mitchell A., Sun Y., and Al-Hashem R. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 9 (2006) 485-495
50. Johnson J.I., Decker S., Zaharevitz D., Rubinstein L.V., Venditti J.M., Schepartz S., Kalyandrug S., Christian M., Arbuck S., Hollingshead M., and Sausville E.A. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br. J. Cancer 84 (2001) 1424-1431
51. Kaminski M.S., Tuck M., Estes J., Kolstad A., Ross C.W., Zasadny K., Regan D., Kison P., Fisher S., Kroll S., and Wahl R.L. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N. Engl. J. Med. 352 (2005) 441-449
52. Killion J.J., Radinsky R., and Fidler I.J. Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev. 17 (1998) 279-284
53. Kim C.F., Jackson E.L., Woolfenden A.E., Lawrence S., Babar I., Vogel S., Crowley D., Bronson R.T., and Jacks T. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 121 (2005) 823-835
54. Kohl N.E., Omer C.A., Conner M.W., Anthony N.J., Davide J.P., deSolms S.J., Giuliani E.A., Gomez R.P., Graham S.L., Hamilton K., Handt L.K., Hartman G.D., et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat. Med. 1 (1995) 792-797
55. Kong D., Park E.J., Stephen A.G., Calvani M., Cardellina J.H., Monks A., Fisher R.J., Shoemaker R.H., and Melillo G. Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res. 65 (2005) 9047-9055
56. Kung A.L., Zabludoff S.D., France D.S., Freedman S.J., Tanner E.A., Vieira A., Cornell-Kennon S., Lee J., Wang B., Wang J., Memmert K., Naegeli H.U., et al. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 6 (2004) 33-43
57. Lane D.P. Cancer. p53, guardian of the genome. Nature 358 (1992) 15-16
58. Laurie N.A., Gray J.K., Zhang J., Leggas M., Relling M., Egorin M., Stewart C., and Dyer M.A. Topotecan combination chemotherapy in two new rodent models of retinoblastoma. Clin. Cancer Res. 11 (2005) 7569-7578
59. Lemieux B., and Coiffier B. Radio-immunotherapy in low-grade non-Hodgkin's lymphoma. Best. Pract. Res. Clin. Haematol. 18 (2005) 81-95
60. Lenferink A.E., Pinkas-Kramarski R., van de Poll M.L., van Vugt M.J., Klapper L.N., Tzahar E., Waterman H., Sela M., van Zoelen E.J., and Yarden Y. Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J. 17 (1998) 3385-3397
61. Levitzki A., and Bohmer F.D. Altered efficacy and selectivity of tyrosine kinase inhibitors of the activated states of protein tyrosine kinases. Anticancer Drug Des. 13 (1998) 731-734
62. Levitzki A., and Mishani E. Tyrphostins and other tyrosine kinase inhibitors. Annu. Rev. Biochem. 75 (2006) 93-109
63. Luo J., Manning B.D., and Cantley L.C. Targeting the PI3K-Akt pathway in human cancer: Rationale and promise. Cancer Cell 4 (2003) 257-262
64. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., Louis D.N., Christiani D.C., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 (2004) 2129-2139
65. Matar P., Rojo F., Cassia R., Moreno-Bueno G., Di Cosimo S., Tabernero J., Guzman M., Rodriguez S., Arribas J., Palacios J., and Baselga J. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): Superiority over single-agent receptor targeting. Clin. Cancer Res. 10 (2004) 6487-6501
66. Milyavsky M., Tabach Y., Shats I., Erez N., Cohen Y., Tang X., Kalis M., Kogan I., Buganim Y., Goldfinger N., Ginsberg D., Harris C.C., et al. Transcriptional programs following genetic alterations in p53, INK4A, and H-Ras genes along defined stages of malignant transformation. Cancer Res. 65 (2005) 4530-4543
67. Miyamoto T., Weissman I.L., and Akashi K. AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8; 21 chromosomal translocation. Proc. Natl. Acad. Sci. USA 97 (2000) 7521-7526
68. Nagane M., Levitzki A., Gazit A., Cavenee W.K., and Huang H.J. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc. Natl. Acad. Sci. USA 95 (1998) 5724-5729
69. Nagane M., Narita Y., Mishima K., Levitzki A., Burgess A.W., Cavenee W.K., and Huang H.J. Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor. J. Neurosurg. 95 (2001) 472-479
70. Nagar B., Bornmann W.G., Pellicena P., Schindler T., Veach D.R., Miller W.T., Clarkson B., and Kuriyan J. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62 (2002) 4236-4243
71. O'Hare T., Walters D.K., Stoffregen E.P., Jia T., Manley P.W., Mestan J., Cowan-Jacob S.W., Lee F.Y., Heinrich M.C., Deininger M.W., and Druker B.J. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 65 (2005) 4500-4505
72. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H., et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
73. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., Kris M.G., and Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2 (2005) e73
74. Pastan I. Immunotoxins containing Pseudomonas exotoxin A: A short history. Cancer Immunol. Immunother. 52 (2003) 338-341
75. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., Gianni L., Baselga J., Bell R., Jackisch C., Cameron D., Dowsett M., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353 (2005) 1659-1672
76. Pietras R.J., Fendly B.M., Chazin V.R., Pegram M.D., Howell S.B., and Slamon D.J. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 9 (1994) 1829-1838
77. Pietras R.J., Poen J.C., Gallardo D., Wongvipat P.N., Lee H.J., Slamon D.J., Fendly B.M., Chazin V.R., Pegram M.D., and Howell S.B. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Cancer Res. 59 (1999) 1347-1355
78. Politi K., Zakowski M.F., Fan P.-D., Schonfeld E.A., Pao W., and Varmus H.E. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors 10.1101/gad.1417406. Genes Dev. 20 (2006) 1496-1510
79. Powis G., and Kirkpatrick L. Hypoxia inducible factor-1alpha as a cancer drug target. Mol. Cancer Ther. 3 (2004) 647-654
80. Ptasznik A., Nakata Y., Kalota A., Emerson S.G., and Gewirtz A.M. Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Nat. Med. 10 (2004) 1187-1189
81. Robanus-Maandag E., Dekker M., van der Valk M., Carrozza M.L., Jeanny J.C., Dannenberg J.H., Berns A., and te Riele H. p107 is a suppressor of retinoblastoma development in pRb-deficient mice. Genes Dev. 12 (1998) 1599-1609
82. Roche-Lestienne C., and Preudhomme C. Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment. Semin. Hematol. 40 (2003) 80-82
83. Roche-Lestienne C., Soenen-Cornu V., Grardel-Duflos N., Lai J.L., Philippe N., Facon T., Fenaux P., and Preudhomme C. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100 (2002) 1014-1018
84. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer Jr. C.E., Davidson N.E., Tan-Chiu E., Martino S., Paik S., Kaufman P.A., Swain S.M., Pisansky T.M., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353 (2005) 1673-1684
85. Rosenberg M.P., and Bortner D. Why transgenic and knockout animal models should be used (for Drug efficacy studies in cancer). Cancer Metastasis Rev. 17 (1998) 295-299
86. Rubin B.P., Singer S., Tsao C., Duensing A., Lux M.L., Ruiz R., Hibbard M.K., Chen C.J., Xiao S., Tuveson D.A., Demetri G.D., Fletcher C.D., et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 61 (2001) 8118-8121
87. Schafer A.I. Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood 107 (2006) 4214-4222
88. Schimmer A.D., Welsh K., Pinilla C., Wang Z., Krajewska M., Bonneau M.J., Pedersen I.M., Kitada S., Scott F.L., Bailly-Maitre B., Glinsky G., Scudiero D., et al. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 5 (2004) 25-35
89. Schindler T., Bornmann W., Pellicena P., Miller W.T., Clarkson B., and Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289 (2000) 1938-1942
90. Selivanova G., Kawasaki T., Ryabchenko L., and Wiman K.G. Reactivation of mutant p53: A new strategy for cancer therapy. Semin. Cancer Biol. 8 (1998) 369-378
91. Shah N.P., Nicoll J.M., Nagar B., Gorre M.E., Paquette R.L., Kuriyan J., and Sawyers C.L. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2 (2002) 117-125
92. Shah N.P., Tran C., Lee F.Y., Chen P., Norris D., and Sawyers C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305 (2004) 399-401
93. Shechter Y., Yaish P., Chorev M., Gilon C., Braun S., and Levitzki A. Inhibition of insulin-dependent lipogenesis and anti-lipolysis by protein tyrosine kinase inhibitors. EMBO J. 8 (1989) 1671-1676
94. Shet A.S., Jahagirdar B.N., and Verfaillie C.M. Chronic myelogenous leukemia: Mechanisms underlying disease progression. Leukemia 16 (2002) 1402-1411
95. Shir A., and Levitzki A. Commentary: Gene therapy for glioblastoma: Future perspective for delivery systems and molecular targets. Cell. Mol. Neurobiol. 21 (2001) 645-656
96. Shir A., Ogris M., Wagner E., and Levitzki A. EGF receptor-targeted synthetic double-stranded RNA eliminates glioblastoma, breast cancer, and adenocarcinoma tumors in mice. PLoS Med. 3 (2006) e6
97. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., Henkelman R.M., Cusimano M.D., and Dirks P.B. Identification of human brain tumour initiating cells. Nature 432 (2004) 396-401
98. Sordella R., Bell D.W., Haber D.A., and Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305 (2004) 1163-1167
99. Taketo M.M. Mouse models of gastrointestinal tumors. Cancer Sci. 97 (2006) 355-361
100. Tamura K., and Fukuoka M. Gefitinib in non-small cell lung cancer. Expert Opin. Pharmacother. 6 (2005) 985-993
101. Tokarski J.S., Newitt J.A., Chang C.Y.J., Cheng J.D., Wittekind M., Kiefer S.E., Kish K., Lee F.Y.F., Borzillerri R., Lombardo L.J., Xie D., Zhang Y., et al. The Structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants 10.1158/0008-5472.CAN-05-4187. Cancer Res. 66 (2006) 5790-5797
102. Tsai C.M., Levitzki A., Wu L.H., Chang K.T., Cheng C.C., Gazit A., and Perng R.P. Enhancement of chemosensitivity by tyrphostin AG825 in high-p185(neu) expressing non-small cell lung cancer cells. Cancer Res. 56 (1996) 1068-1074
103. Vermeulen K., Berneman Z.N., and Van Bockstaele D.R. Cell cycle and apoptosis. Cell Prolif. 36 (2003) 165-175
104. Vogelstein B., and Kinzler K.W. Cancer genes and the pathways they control. Nat. Med. 10 (2004) 789-799
105. von Bubnoff N., Manley P.W., Mestan J., Sanger J., Peschel C., and Duyster J. Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood 108 (2006) 1328-1333
106. Voskoglou-Nomikos T., Pater J.L., and Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin. Cancer Res. 9 (2003) 4227-4239
107. Warburg O. On the origin of cancer cells. Science 123 (1956) 309-314
108. Warner J.K., Wang J.C., Hope K.J., Jin L., and Dick J.E. Concepts of human leukemic development. Oncogene 23 (2004) 7164-7177
109. Xia W., Bacus S., Hegde P., Husain I., Strum J., Liu L., Paulazzo G., Lyass L., Trusk P., Hill J., Harris J., and Spector N.L. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc. Natl. Acad. Sci. USA 103 (2006) 7795-7800
110. Yaish P., Gazit A., Gilon C., and Levitzki A. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 242 (1988) 933-935
111. Yeon C.H., and Pegram M.D. Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. Invest. New Drugs 23 (2005) 391-409
112. Yoneda T., Lyall R.M., Alsina M.M., Persons P.E., Spada A.P., Levitzki A., Zilberstein A., and Mundy G.R. The antiproliferative effects of tyrosine kinase inhibitors tyrphostins on a human squamous cell carcinoma in vitro and in nude mice. Cancer Res. 51 (1991) 4430-4435
113. Zhang X., Gureasko J., Shen K., Cole P.A., and Kuriyan J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125 (2006) 1137-1149